Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

🤖 Plain-English Summary

BACKGROUND: The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. CONCLUSIONS: A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.

🔑 Key Findings

• The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence.
• The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
• METHODS: We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk.

🔗 Related Resources